| Dec 22 | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | |||||
| Gross Profit | $ 121.00K | $ 113.00K | - | - | - |
| Operating Income | $ -70.80M | $ -61.56M | $ -18.76M | $ -29.75M | $ -9.15M |
| EBITDA | $ -73.47M | $ -63.10M | $ -18.94M | $ -51.23M | $ -9.18M |
| Net Income | $ -73.53M | $ -66.05M | $ -19.10M | $ -51.26M | $ -9.24M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ ― | $ ― | $ ― | $ ― | $ ― |
| Total Assets | $ 22.75M | $ 83.50M | $ 17.49M | $ 11.10M | $ 3.76M |
| Total Debt | $ 20.12M | $ 18.96M | $ 9.72M | $ 0.00 | $ 0.00 |
| Net Debt | $ 4.62M | $ -59.78M | $ -5.94M | $ -10.26M | $ -3.58M |
| Total Liabilities | $ 33.36M | $ 26.18M | $ 14.92M | $ 11.10M | $ 1.19M |
| Stockholders' Equity | $ ― | $ ― | $ ― | $ ― | $ ― |
| Cash Flow | |||||
| Free Cash Flow | $ -61.60M | $ -48.99M | $ -20.91M | $ -19.30M | $ -8.13M |
| Operating Cash Flow | $ -61.60M | $ -48.99M | $ -20.91M | $ -19.30M | $ -8.13M |
| Investing Cash Flow | |||||
| Financing Cash Flow |
Seelos Therapeutics (DE:NXE)
FRANKFURT:NXE
